Know Cancer

forgot password

A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers

18 Years
80 Years
Open (Enrolling)
Malignant Tumor

Thank you

Trial Information

A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers

Inclusion Criteria:

- Females 18 to 80 years of age

- Tumor is well visualized through x-ray mammography or ultrasound imaging and
amenable to image guidance therapy (a tumor which is well visualized through imaging
can be identified from surrounding breast tissue and does not have margins

- obscured by other structures or artifacts on the images)

- Tumor must be well visualized (as defined above) on MRI

- Definitive pathologic diagnosis by needle core biopsy

- Unifocal malignant tumor that does not exceed 20mm in diameter and measures at least
5mm away from the skin and chest wall

- Cluster of microcalcifications that do not exceed 10 mm in diameter and measures at
least 5mm away from the skin and chest wall

- Subjects with or without palpable lymph nodes

- Subjects with mammographic appearance of overall dense parenchymal tissue may be
included, as long as a clearly evident marker is present at tumor site

- Subjects with less than 25% intraductal component

- Subject has no clinically significant co-morbidities (i.e. chronic illnesses existing
simultaneously with and usually independent of breast cancer) that affect life
expectancy. Subject has given written informed consent

- Subject agrees to comply with follow up visits

Exclusion Criteria:

- Subjects younger than 18 years of age

- Pregnant or breast-feeding women

- Tumors poorly visualized by x-ray mammography or ultrasound imaging

- Women who are morbidly obese (>300 lbs)

- Acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR)
<30ml/min/1.73 sq.meters)

- Moderate to end-stage kidney disease and a history of severe asthma or allergies

- Tumors measuring greater than 20mm in diameter

- Subjects with advanced stage breast cancer

- Subjects with prior history of cancer in the ILT treated breast

- Subjects with recurrent breast cancer

- Subjects with lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phylloides
tumor, or Paget's disease

- Subjects with benign vascular tumor

- Subjects with benign lesions such as fibroadenoma, atypical ductal hyperplasia,
sclerosing adenosis, Papilloma, fibrocystic disease of breast

- Subjects with DCIS with microinvasion

- Subjects with a cluster of microcalcifications whose diameter is larger than 10 mm.

- Subjects with extensive intraductal component and other characteristics not well
visualized by imaging studies

- Subjects who are BRCA positive.

- Inability to lie prone or supine for one hour

- Currently participating or enrolled in another investigational treatment, device or
drug study through follow up

- Undergoing concurrent neoadjuvant therapies for breast cancer

- Cardiac pacemaker or other metallic implants which would prevent patient from safely
undergoing MRI scan

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Collect information on the proportion of tumors ablated for sample size calculations in the pivotal trial

Outcome Description:

Evaluate the rate of complete tumor ablation by Novilase ILT of small breast cancers and characterize the correlation of imaging (MR, US, x-ray) in detecting residual post ablation with histopathology of the excised specimen. An individual patient will be considered to have a complete ablation if the pathology results post excision demonstrates that no visible gross residual tumor is present.

Outcome Time Frame:

one month end point

Safety Issue:


Principal Investigator

Barbara Schwartzberg, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rose Breast Center


United States: Food and Drug Administration

Study ID:




Start Date:

April 2012

Completion Date:

Related Keywords:

  • Malignant Tumor
  • Unifocal
  • 20mm in diameter
  • measures
  • 5mm away from the skin and chest
  • Breast Neoplasms
  • Neoplasms



University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma  73104
Rose Breast Center Denver, Colorado  80220
St. Alexius Breast Care of St. Alexius Medical Center Bartlett, Illinois  60103